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Abstract
Routine follow-up visits and radiographic imaging are required for outcome evaluation and tumor recurrence monitoring. Yet
more personalized surveillance is required in order to sufficiently address the nature of heterogeneity in nonsmall cell lung
cancer and possible recurrences upon completion of treatment. Radiomics, an emerging noninvasive technology using medical
imaging analysis and data mining methodology, has been adopted to the area of cancer diagnostics in recent years. Its potential
application in response assessment for cancer treatment has also drawn considerable attention. Radiomics seeks to extract a
large amount of valuable information from patients’ medical images (both pretreatment and follow-up images) and quantita-
tively correlate image features with diagnostic and therapeutic outcomes. Radiomics relies on computers to identify and
analyze vast amounts of quantitative image features that were previously overlooked, unmanageable, or failed to be identified
(and recorded) by human eyes. The research area has been focusing on the predictive accuracy of pretreatment features for
outcome and response and the early discovery of signs of tumor response, recurrence, distant metastasis, radiation-induced
lung injury, death, and other outcomes, respectively. This review summarized the application of radiomics in response
assessments in radiotherapy and chemotherapy for non-small cell lung cancer, including image acquisition/reconstruction,
region of interest definition/segmentation, feature extraction, and feature selection and classification. The literature search for
references of this article includes PubMed peer-reviewed publications over the last 10 years on the topics of radiomics, textural
features, radiotherapy, chemotherapy, lung cancer, and response assessment. Summary tables of radiomics in response
assessment and treatment outcome prediction in radiation oncology have been developed based on the comprehensive
review of the literature.
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Introduction
Lung cancer is one of the most common cancer in the world,
accounting for the first place in men (16.7%) and third in
women (8.7%).1 When cancer is suspected, further confirma-
tion and follow-up are required in order to assist clinicians with
accurate diagnosis and develop properly indicated treatment
regimens. Tumor biopsy and physiology analysis are the most
accurate way for diagnosis. Yet biopsy has limitations, that is,
the location of tumor biopsied may strongly affect physiology
results.2 Medical imaging systems are noninvasive approaches
for tumor assessment and they provide substantial benefits, that
is, tumor’s biological and functional information and its sur-
rounding microenvironment,3 beyond simple tumor visualiza-
tion with newly developed contrast and tracer agents.
Diagnostic interpretation of medical images has become more
sophisticated and focused on disease types. For instance, most
tumors exhibit heterogeneity, both spatially and temporally,
which can be visualized and tracked with new radiomics
applications on chest radiographs and computed tomography
(CT) images. Lambin et al4 was the first to introduce the
concept of “radiomics” in 2012 and presented its key tech-
nique and application prospects. Kumar et al5 further
expanded the definition and analyzed the challenges of each
step of its workflow, especially for lung cancer in the same
year. Radiomics is essentially derived from the concept of
computer-aided diagnosis, which uses computer assistance
in processing a large number of imaging features extracted
from various imaging modalities, including CT, positron
emission tomography (PET), magnetic resonance imaging,
and/or other medical imaging modalities.4,5 This strategy
transforms the regions of interest (ROIs) into high-
resolution, minable data by introducing the big data technol-
ogy and using automatic data feature algorithms.5 Adopted
from radiology, this technique has been recently explored in
cancer treatments, including tumor targeted drug therapy,6
preoperative assessment of tumor surgery,7,8 and response
and outcome assessments after radiotherapy and systemic
therapy.9-13
The applications of radiomics for non-small cell lung cancer
(NSCLC) include (1) treatment efficacy and response evalua-
tion, (2) to assist noninvasive early diagnosis, and (3) predic-
tion of treatment outcomes. It becomes possible to detect tumor
occurrence at an early stage, as well as to predict treatment
efficacy and detect recurrence or metastasis after a given treat-
ment regime of radiation and/or systemic therapy.9,14 With the
established database, care providers can now more practically
predict treatment outcomes and possible radiation-induced
injuries and seek out personalized and precise treatment
options for patients.15
Previous review articles have provided summaries of radio-
mics analysis approaches, mathematical algorithms, and clin-
ical applications in diagnosis, prognosis, or outcome
predictions.5,16-18 In 2014, Mattonen et al10 reviewed novel
techniques focusing on quantitative imaging feature analysis
for response assessment after radiotherapy for lung cancer. In
2016, Parekh and Jacobs17 summarized approaches and math-
ematical algorithms applied to lung, breast, liver, and so on.
The development of radiomics and its application have also
been discussed in various aspects.19-21 More recently, several
papers reviewed related texture analysis applied to PET/CT
images for tumor response assessment16,22,23 in the past 2
years. Scrivener et al2 and Lee et al18 focused on the applica-
tion to lung cancer, while Sollini et al24 proposed harmonizing
PET radiomics methods for their applications in NSCLC.
Radiomics currently plays an important role in providing a
fundamental methodology for future personalized treatment
and follow-up in the era of precision medicine. Our focus is
to elaborate the specific applications of radiomics in the con-
text of radiotherapy with or without systemic regimen for
NSCLC and its current research developments using CT and
PET images. A comprehensive literature search was conducted
using the PubMed database to include papers published from
the year of 2007 to present, with the keywords of radiomics,
textural features, radiotherapy, systemic therapy, chemother-
apy, lung cancer, and response assessment. Summary tables
in response assessment and treatment outcome prediction in
radiation oncology have been developed based on the compre-
hensive review of the literature.
The Workflow of Radiomics
The workflow of radiomics, as shown in Figure 1, includes (1)
imaging acquisition/reconstruction, (2) ROI definition/seg-
mentation, (3) image feature extraction, and (4) image feature
selection and classification. Research interests have been
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widely focused on metrologies and challenges, as well as clin-
ical applications of these aspects. Herein we describe in details
various stages in the radiomics workflow.
Imaging Acquisition and Reconstruction
Acquiring high-quality and standardized images is a prere-
quisite for the accuracy and consistency of radiomics data.
A large amount of the standardized image data can help
establish a response assessment model to predict the prob-
ability of recurrence and metastasis after treatment.6,25
Within those 2 commonly available types of image acqui-
sition modalities for treating NSCLC, CT and PET, choos-
ing a consistent image modality for the diagnosis and
follow-up scans is essential to avoid divergence and discor-
dance in the extracted feature data. In addition, even for the
same imaging modality, the variations in acquisition para-
meters (kV, mAs, slice thickness, breathing control method,
configurations, field strength, and contrast media) and
reconstruction parameters (reconstruction kernels or filters)
are likely to affect image values for scanning the exact same
subject, which might complicate the process of ROI-based
image segmentation and feature extraction.5,26-30 Thus, it is
essential to maintain homogeneity in image scan protocols
for a radiomics study.
Region of Interest Segmentations
Image segmentation for ROI creations is a crucial step, which
directly affects the quality of subsequent feature extraction,
thus affects the correctness and accuracy of research
results.20,31 Segmentation includes manual, semiautomatic, and
automatic segmentations. Manual segmentation means that an
experienced physician manually delineates the ROI on images,
which is currently the most widely used method.28,32 Manual
segmentation has minimal needs in specialized algorithms but
demands user specialty and experience. It is also time-
consuming and can have significant intra- and interobserver
variability, which may cause obstacles in big data analysis.33
The automatic segmentation does not require manual inter-
vention and functions through computer-aided automation
with preset parameters. However, it relies on the accuracy
of algorithms and their ability to differentiate ROIs from
surrounding tissues. Semiautomatic segmentation takes
advantages of both manual intervention and software
automation, which makes it a preferable method for radiomics
data analysis.5,14,19,34 Semiautomatic segmentation that uses
computer segmentation method cannot be reliably used alone.
Further manual intervention is needed to ensure the accuracy
of segmentation.35
Reproducibility of quantitative PET and CT image features
in NSCLC concerning variations caused by segmentation
methods and patient factors had been studied and proved
stable.36-41 Several studies used intraclass correlation coeffi-
cient (ICC)42 to compare the repeatability in manual, auto-
matic, and semiautomatic segmentation methods.36,38,39
Among them, Parmar et al39 concluded that semiautomatic
features provide higher reproducibility than manual segmenta-
tions (ICC: 0.85+ 0.15 vs 0.77+ 0.17). Semiautomatic multi-
seed point segmentation can generate stable segmented
volumes with similarity index above 0.93, compared to
0.73 in manual segmentation.41 Overall, ROI identification and
segmentation are critical factors in the process of imaging
analysis and feature extraction.43,44
Image Feature Extraction
Exploring possible correlations between image feature infor-
mation with tumors’ phenotypes and prognostics is currently
the main interest in radiomics research. Publications have
shown potential diagnostic and prognostic powers from
Figure 1. The workflow of radiomics.
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radiomics signatures for lung patients.45-50 Present literatures
have reported clinical factors, conventional features, and tex-
ture features for radiomics or delta-radiomics studies.19,45,51-56
Different from clinical factors and conventional features that
are acquired from hospital records or radiology readings, tex-
ture features are calculated mathematically by software plat-
forms, such as MATLAB or Python. Texture feature is the
spatial distribution of gray-level intensity in images and ana-
lyzed by 2 main mathematical techniques in NSCLC: statistical
methods and transform-based methods, of which the first one is
most used for lung cancer.6,16,32,45,51,57 More specific descrip-
tion of radiomics features are summarized in Table 1. Cur-
rently, one of the predictive models is established based on
size, concavity, contour, and spiculation.48 In fact, the size-
based features can be good predictors of cancerous nodules
by itself and has significant correlation with overall survival
(OS).46 Additionally, the diversity of image features, such as
tumor’s growth rate and volume change, and multivariate anal-
ysis can improve prediction accuracy.46,51 It is even possible to
determine benign or malignant lymph nodes status by using CT
texture features.49,50 More significant features are to be discov-
ered and validated.
Feature Selection and Classification
Feature selection and classification are also crucial after
extracting a large number of features, most of which may
be noise or intercorrelated features. The procedure of
selecting and classifying features is to reduce the dimen-
sion.28,58 There are a few publications on comparing the
abilities of different feature selection methods and machine
learning classifying methods to predict outcomes for
lung.58,59
Feature selection preserves a subset of useful and unique
features, reducing the computational costs and increasing the
accuracy of predation, which can be applied to supervised and
unsupervised learning.60,61 Previous research had demon-
strated that Wilcoxon selection method had highest perfor-
mance in supervised learning,62 while principal component
analysis58 had higher prediction performance than Wilcoxon
(area under the receiver operating characteristic curve [AUC]
¼ 0.70. vs 0.67) in unsupervised learning.58 Feature selection
algorithms, that is, filtering, wrapper, and embedded methods,
have their merits and demerits.60,63 The filtering methods are
independent of the chosen predictors, with efficient numeracy
and statistical scalability, which can reduce dimensionality
Table 1. Features Extracted From PET and/or CT Images.
Class Type Method Feature Name
Clinical factors Age, gender, histology type, stage, etc
Conventional features PET only SUV metrics SUVmean
SUVmax
SUVpeak
COV
SD
AUC-SCH
TLG
MTV
CT only HU metrics Mean
Maximum
COV
SD
PET/CT Size, shape, volume, diameter, solidity, eccentricity, etc
Texture features (PET/CT) First order IVH Mean, variance, skewness, kurtosis, energy, entropy
Law’s Level, edge, spot, wave, ripple
High order GLCM Contrast, correlation, entropy, dissimilarity, energy, and so on
GLRLM Run percentage
Short run emphasis
Long run emphasis
Gray-level nonuniformity
Run-length nonuniformity
GLSZM Zone size percentage
Zone size nonuniformity
Gray-level nonuniformity, etc.
NGTDM Coarseness, contrast, busyness, complexity, texture strength
Transform based Wavelet, Fourier, LoG
Abbreviations: AUC-CSH, area under the curve of the cumulative SUV-volume histogram; COV, coefficient of variation; CT, computed tomography; GLCM,
gray-level co-occurrence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix; HU, Hounsfield unit; IVH, intensity–volume
histogram; Law’s, Law’s texture measures; LoG, Laplacian transform of Gaussian filter; MTV, metabolic tumor volume; NGTDM, neighborhood gray-tone
difference matrix; PET, positron emission tomography; SD, standard deviation; SUV, standardized uptake value; SUVmax, maximum SUV; SUVmean, average
SUV; SUVpeak, peak SUV; TLG, total lesion glycolysiss.
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and overfitting compared to the wrapper and embedded meth-
ods.63 Comparison of 14 filter feature selection methods indi-
cated that Wilcoxon selection has the highest performance in
predicting OS (AUC ¼ 0.65+ 0.02) with maximum stability
(0.84 + 0.05).62
Among the two feature classifications, that is, supervised
and unsupervised classifiers, the former requires user to pro-
vide patients’ radiomics features and outcomes as training data
(ie, support vector machines, random forest, decision tree,
neural networks, boosting, discriminant analysis, k-nearest
neighbors, etc),64-68 while the latter doesn’t require outcome
data (ie, consensus clustering, k-means clustering, hierarchical
clustering, etc).17 Parmar et al62 and Zhang et al58 proved that
random forest classifier has the highest prediction performance
in OS (AUC ¼ 0.66 and 0.71).
Moreover, a combination of different feature selection
methods and classifiers can achieve different prediction
results. It was found that a combination of Wilcoxon selec-
tion model with random forest classifier has the best per-
formance for predicting OS, while near-zero variance
selection model combined with random forest classifier is
appropriate for predicting recurrence (AUC ¼ 0.76), and
zero variance selection model with naive Bayes classifier
is the best to predict death (AUC ¼ 0.77), and mixture
discriminant analysis classifier alone (AUC ¼ 0.73) was
best for predicting recurrence-free survival .58 Identification
of feature selection methods, classification methods, and
analyzing tools is a crucial step for improving accuracy,
stability, and performance of features for assessing response
and predicting clinical outcomes. Radiomics is an emerging
area, so does the development of feature selection and clas-
sification algorithms. The optimal method is still being
developed based on clinical needs.
Radiomics in Response and
Outcome Evaluation
Literature on applying radiomics to assess response and predict
treatment outcome for lung is based on pretreatment images
(Table 2) and follow-up images (Table 3). Pretreatment ima-
ging radiomics is used to discover the association of quantita-
tive features extracted from images taken prior to treatment
with response and outcomes monitored upon treatment com-
pletion. The focus of these studies is on the ability of predicting
prognosis from the pretreatment features.8,52,74,75 Delta-
radiomics is a method that compares the changes within those
features extracted from pretreatment images and follow-up
images during and/or after the treatment, in order to identify
signs of recurrence, metastases, or other morality.15,56,77,81,83
Positron emission tomography and CT images have been
widely used for lung patients and thus are readily available for
radiomic analysis. Positron emission tomography images pro-
vide molecular metabolic information and thus detect disease
early, while CT provides anatomical characteristics. The end
points mostly studied in PET images are Response Evaluation
Criteria in Solid Tumors (RECIST)-based responses12,13,79 and
outcomes, such as recurrence,52,53,69,78,81 distant metastases
(DM),57,69 and survival.54,55,71,72 The end points in CT images
focus on pathological response, mutation status, and distin-
guishing radiation-induced lung injury (RILI). The image fea-
tures with high correlation to those end points are listed in
Tables 2 and 3. Most of these study trials are retrospective,
thus patients’ images along with clinical outcome data are
achieved from records of medical institutions or hospitals.
Tumor Response Assessments
Positron emission tomography images. Tumor response studied in
PET images including stable disease and progress disease is
assessed by the RECIST and divided into 3 types: complete
response, partial response, and nonresponse.12,13,79 The
extracted features are pretreatment standardized uptake value
(SUV) metrics, metabolic tumor volume (MTV), total lesion
glycolysis, quantitative texture features, such as entropy, cor-
relation, contrast, and uniformity, and “delta-radiomics.”
Among them, texture features outperformed others in predict-
ing tumor response to treatment. Cook et al12,13 showed that
texture features measured by coarseness, contrast, and busy-
ness presented strong correlations with RECIST response to
chemoradiotherapy (CRT; P ¼ .004, .002, .027), while SUV
parameters showed none. Texture features reflecting reduced
heterogeneity measured by first-order standard deviation (SD),
entropy, and uniformity (P < .01, ¼ .001, ¼ .001) also pre-
sented a stronger correlation with RECIST response to erlotinib
than SUV metrics. Dong et al79 found that even though pre-
treatment features, such as coefficient of variation, MTV, and
contrast (AUC ¼ 0.781, 0.686, 0.804) had a predictive capa-
bility for response to CRT, early changes in texture features can
better predict response with higher specificity (80%-83.6%)
and sensitivity (73.2%-92.1%).
Computed tomography images. Different from RECIST
responses studied in PET images, tumor response studied in
CT images mainly focuses on pathological response, and treat-
ment responses such as tumor response to radiation and epider-
mal growth factor receptor (EGFR) mutation status reflected
gefitinib response.6-8,86,87 In terms of predicting pathological
response, pretreatment primary tumor sphericity, texture fea-
tures, lymph node homogeneity, and changes in primary tumor
volume, mass, histogram features, and texture features are
potential predictors for patients with NSCLC after CRT, while
primary tumor intensity variability and size zone variability are
predictive for patients after tyrosine kinase inhibitor ther-
apy.7,86 It is also found that lymph node phenotype has a better
performance in classifying pathologic complete response and
gross residual disease than primary tumor.7 A study tracked
tumor response to radiation in daily CT images during radio-
therapy course found that reductions in mean Hounsfield unit
(HU) in gross tumor volume (GTV) had a strong correlation
with accumulated GTV dose (R2 > 0.99) and were significantly
associated with survival rate.87 In predicting EGFR mutation
status and reflected gefitinib response, a pretreatment Law’s
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texture feature and changes in volume, maximum diameter, and
a filter-based feature were proved significant.
The RECIST response has its limitation in diversified clin-
ical applications.88 Radiomic features such as texture features
and volume changes have the potential to better predict tumor
responses and thus may be considered as new tumor response
phenotypes that provide diversified information in the future.
Survival Analysis
Studies focusing on survival analysis include OS, progression-
free survival (PFS), locoregional recurrence-free survival
(LRFS), distant metastasis–free survival (DMFS), disease-
free survival (DFS), disease-specific survival (DSS), and so on.
Positron emission tomography images. For predicting survivals
based on PET images, the best features ever found are: the
high-order contrast for OS (P ¼ .002),12 AUC of the cumula-
tive SUV-volume histogram (AUC-CSH) for PFS, LRFS, and
DMFS (P < .001,¼ .002,¼ .003),54 and mean SUV (SUVmean)
greater than 3.45 for DSS (P ¼ .007).78 Kang et al54 revealed
that maximum SUV (SUVmax) and AUC-CSH reflecting tumor
heterogeneity were significant prognostic factors for PFS,
while AUC-CSH were for LRFS and DMFS.54 Carvalho et
al55 showed that tumor’s relative volume containing >80%
SUV significantly correlates with OS, and a larger tumor’s
relative volume above a higher SUV can lead to better prog-
nosis. Furthermore, the texture feature SumMean for OS by
Ohri et al71 and textural feature dissimilarity for DSS and DFS
by Lovinfosse et al70 are shown to be more powerful indepen-
dent predictors compared to metabolic metrics. Aside from
these features, conventional clinical factors, such as gender,
age, histology, stage, and so on, have also been discussed by
Lovinfosse et al70 and Fried et al72 The latter showed that the
combination of quantitative features with conventional clinical
features can improve OS risk stratification compared with con-
ventional clinical features alone.72 In addition, delta-radiomics
features of fludeoxyglucose-PET are correlated with OS in
patients with NSCLC. Carvalho et al80 validated the predictive
capacity in delta-radiomics features (volume, texture features,
and intensity–volume histogram [IVH]) and demonstrated their
correlations with OS.
Computed tomography images. Radiomics features in CT images
can predict OS better than PET images. A radiomics model
based on pretreatment CT and recalibrated cone beam CT
images in van Timmeren et al study (concordance index ¼
0.69, P ¼ 4.0  1010) and a combination model of pretreat-
ment features and delta radiomics features in Fave et al’s
study (c-index ¼ 0.675; P ¼ 1.3  105) are significant pre-
dictors for OS.74,85,89 Overall, in survival studies based on CT
images, those radiomics features quantifying shapes, intensity,
and texture, conventional features (such as Eastern Cooperative
Oncology Group performance status, pleural retraction, and
diameter), and delta-radiomics features are predictive, and
when they are combined with clinical factors, the predictive
capacity can be significantly improved.32,45,74,85
Recurrence Prediction After Treatment
Positron emission tomography images. For recurrence prediction
after treatment based on PET images, SUV metrics and texture
features were both discussed in recent literature. Takeda et al,81
Essler et al78 and Zhang et al53 assessed local recurrence (LR)
in patients with NSCLC after stereotactic body radiotherapy
(SBRT) by PET images and showed SUV metrics as strong LR
predictors, that is, dual-time-point SUVmax or SUVmaxs in the
study by Takeda et al,81 SUVmean >3.44, SUVmax > 5.48, and
their reduction in the study by Essler et al,78 and the cutoff
SUVmax of 5 with 100% sensitivity and 91% specificity in the
study by Zhang et al53 However, SUV metrics are reported less
correlated when compared with other features, such as IVH,
texture features, and so on. Pyka et al69 assessed the relation-
ship of texture features with LR in PET images for patients
with NSCLC after radiotherapy and reported that several tex-
ture features such as entropy (AUC ¼ 0.872) and correlation
(AUC ¼ 0.816) had higher AUC values than SUV metrics in
receiver operating characteristic analysis.
Computed tomography images. Computed tomography–based
radiomics features exhibited lack of prognostic power for
locoregional recurrence (LRR) in many studies,28,32 while 5
pretreatment statistic and texture features in the study by
Huynh et al and end-treatment texture-strength feature in the
study by Fave et al are prognostic for LR, and 3 pretreatment
statistic and texture features in Huynh et al are prognostic for
lobar recurrence.28,32,81,85 Although CT-based radiomic fea-
tures are limited in their ability to predict recurrence compared
to other outcomes, they have the ability to distinguish tumor
recurrences on follow-up CT images earlier than human eyes.
Mattonen et al83 compared the predictive ability between doc-
tors and radiomic features. Although physicians’ average pre-
dictive accuracy rate was 83% for the average prediction period
of 15.5 months, they misdiagnosed at an average error rate of
35%, a false-positive rate (FPR) of 1%, and a false-negative
rate (FNR) of 99% when the follow-up period was shortened to
6 months after radiotherapy. In contrast, the studied five radio-
mics features can accurately determine the recurrence rate with
AUC value of 0.85, classification error rate of 24%, FPR of
24%, FNR of 23% at 6 months.
These recurrence studies show that PET features own higher
predictive abilities and accuracy in tumor recurrence than CT
features.81 Vaidya et al52 also studied the capacity of combined
PET and CT image features, such as SUV or HU, IVH, and
texture features, for LRR prediction in patients with NSCLC
after radiotherapy. It was found that a 2-parameter model of
PET and CT features had higher prediction accuracy for LRR
than PET or CT features alone. Thus, multimodality radiomics
features are superior in predicting tumor recurrence.
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Distinguishing RILI
Computed tomography images. Radiomic features from CT
images also demonstrated high potentials in distinguishing
tumor RILI from recurrence15 and RILI severity levels.84 Mat-
tonen et al15 showed that compared with RILI, tumor recur-
rence showed higher HU,and higher SD in ground-glass
opacity (GGO) texture measure. When comparing conven-
tional features (RECIST and volume) and quantitative
changes in CT number (HU) with GGO textural feature,
results showed the predictive time points to distinguish RILI
and recurrence in advance is 9 months post-SBRT and 15
months post-SBRT, respectively. Another publication by the
same group82 described that GGO textural analysis has
potential to predict recurrence within 5 months post-SBRT.
Similar texture analysis methods were adopted by Moran
et al,84 where first-order and gray-level co-occurrence matrix
texture features were extracted to distinguish RILI severity
levels: none/mild, moderate, and severe. Gray-level co-
occurrence matrix texture features (P ¼ .012-.262; AUC ¼
0.643-0.750) have been reported to provide a better
performance than first-order features (P ¼ .100-.990; AUC ¼
0.543-0.661). Cunliffe et al90 also combined radiomic features
with radiation dose and demonstrated that radiomics can
provide a quantitative, personalized measurement of radiation
dose tolerance for individual patients, which can be used to
determine the possibility of radiation-induced pneumonitis
and monitor its progression.
Distant Metastases Evaluation
Positron emission tomography images. For DM evaluation in PET
images radiomics studies, the optimal prognostic model includ-
ing two quantitative image features of intratumoral heteroge-
neity and average of the voxel with SUVmax of the tumor region
(SUVpeak; c-index¼ 0.71) were shown to be able to predict and
categorize patients into low- and high-risk groups. Further-
more, when tumors’ histologic types were combined, the prog-
nostic power of the model was significantly improved.57
Interestingly, it was presented that neither PET metrics nor
texture features were related to DM in the study by Pyka et al.69
Computed tomography images. For DM evaluation in CT images
radiomics studies, one pretreatment feature describing the
range of voxel intensities (Wavelet LLH stats range;
c-index ¼ 0.67) and seven pretreatment average intensity
projection CT radiomics features describing shape and hetero-
geneity (c-index ¼ 0.638-0.676) in the study by Huynh et al
perform well.28,32 Also, Coroller et al found strong prognostic
powers in radiomic features, among which Laplacian trans-
form of Gaussian (LoG) filter features showed the best per-
formance (c-index ¼ 0.61, P < .001).75 Besides, combining
pretreatment texture features with clinical prognostic factors
can significantly improve their predictive abilities.74,85
It is worth noting that only three studies57,72,80 provided
feature validation. Therefore, even though results were shown
promising, lack of feature validation may lead to false posi-
tive and might shadow doubts in the subsequent correlation
studies.
Current Research Challenges and Prospects
Published studies show promising results in NSCLC treat-
ments, yet there are still major challenges and limitations to
resolve before they can be translated into reliable clinical appli-
cation. A number of experimental clinical studies have found
that current restrictions of radiomics in its therapeutic applica-
tion are mainly subjected to (1) image standardization,29,91 (2)
image registration,92-94 and (3) data sharing.5 The on-going
research activities focusing on tackling these limitations are
elaborated subsequently.
Standardization of Images
Variations in scanning devices, acquisition modes, reconstruc-
tion parameters, and scanning protocols may impact subse-
quent feature analysis as mentioned in “The Workflow of
radiomics”. A study on feature stability in CT perfusion maps
showed that none of radiomics parameters were stable without
standardization, especially for voxel size, temporal resolution,
HU threshold, image discretization, and so on.91 There are two
ways to solve the problem. One is to develop software to cali-
brate existing image data for retrospective analysis. But the
excepted standardization is still difficult to achieve due to the
vast variations in calibration algorithms.95 The other method is
to design prospective trials where all enrolled patients receive
standardized image scans. In addition, there are national image
centers that are currently being planned or constructed, where
images can be obtained within one entity in order to fundamen-
tally resolve the image nonstandardizing issue.19,95
Image Registration
Image registrations, including both rigid and deformable, are
commonly used in the course of radiotherapy treatment of
NSCLC.92 The concept of delta-radiomics demands high
accuracy in image registration when comparing pretreatment
images with posttreatment images and images during treat-
ment. Image registration can be achieved by manual, auto-
matic, or the combination of both.96,97 At present, the
commonly used automatic registration algorithms include
image intensity-based method, and structure-based
method.94,97 Although the impact of image registration on
texture features and change assessment of serial thoracic CT
scans have been studied,93,98,99 it still remains unclear how
image registration accuracy can affect radiomics results and
which method would work the best for delta-radiomics for
NSCLC. Future study areas can be large-scale prospective
clinical trials with the application of delta-radiomics.
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Data Storage and Data Sharing
Radiomics study relies heavily on the statistical analysis.
Sample size is a critical defect in current research. As shown
in Tables 2 and 3, most studies cover limited number of
patients, with one exception that contains a large patient sam-
ple of 647.45 Small sample size poses an obstacle for obtain-
ing high correlations between radiomics features and
treatment outcomes with high confidence interval. Big data
are the premise of using technology to mine the radiomics
features and ensure statistical significance in data analysis.
The establishment of patient database can strengthen standar-
dized management and improve utilization efficiency. The
high-number and high-quality database is the basis for radio-
mics study, in order to effectively predict outcome. Image
data storage and standardization require joint efforts by com-
panies and/or institutions. Institutions such as Cancer Learn-
ing Intelligence Network for Quality and Flatiron Health are
working on data aggregating.100
Additionally, the robustness and stability of the discovered
features need improvement before they are applied to clinical
treatment assistance in NSCLC, so validation and further clin-
ical practice are essential. Future research can also be prospec-
tively designing clinical trials with the focus on implementing
discovered experimental features with high statistical
significance.
Future Developments in Radiomics
for Managing NSCLC
With artificial intelligence being adopted to medical field and
the optimization of machine learning algorithm, limitations in
image preprocessing, that is, ROI segmentation, feature extrac-
tion, and feature selection/classification, may be greatly
improved or even eliminated in a foreseeable future.
The applications are still not adequate to provide satisfac-
tory optimized summary information to direct clinicians in
medical and radiation oncology on how to further manage their
patients, and more “standardized” data are needed from institu-
tions to create these programs. Standardizing is required not only
for image acquisition but also for all the steps in the radiomics
workflow as mentioned in “The Workflow of radiomics”, as
well as all personnel involved, including those in medical and
radiation oncology professions. There is a cultural change under-
way to capture these big data in pursuit of personalized medicine
for patients with NSCLC, and many efforts are underway by
American Society for Radiation Oncology, the American Asso-
ciation of Physicists in Medicine, and American Society of Clin-
ical Oncology to name a few.91
The Cancer Imaging Archive, a National Cancer Institute–
funded information repository that aggregates images (radiol-
ogy, pathology), radiation therapy information objects,
annotations, clinical trial data, and information derived from
quantitative image analysis to support big data analytics, is an
example of a comprehensive approach to acquiring, archiving,
and extracting data that will be useful for the predictive models
that are needed for radiomics to be fully utilized and a great
value to clinicians and their patients.
Conclusion
Radiomics process to assess tumor response and predict recur-
rence, survival, DM, and RILI in NSCLC mainly includes
imaging acquisition/reconstruction, ROI definition/segmenta-
tion, image feature extraction, and image feature selection and
classification. Features quantifying target shape, size, volume,
intensity, texture, and so on, are able to predict outcome and
assess response. Among them, texture features outperform the
others for predicting tumor response, survival, recurrence, DM,
and RILI in PET/CT images and CT images. Delta-radiomics,
which compares the changes within those features extracted
from pretreatment images and follow-up images during and/
or after the treatment, are able to identify signs of recurrence,
metastases, or death early. Image standardization, image reg-
istration, and data sharing are main challenges and limitations
for the clinical applications of radiomics tools. Additionally,
validation and clinical practice are also essential before radio-
mics applied to clinical treatment guidance for NSCLC.
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